US FDA agrees to review Eisai ’s application for Lenvima to treat HCC

The US Food and Drug Administration (FDA) has agreed to review Eisai ’s application for an additional indication of Lenvima (lenvatinib mesylate) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news